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ABSTRACT !
Objective: The objective of this systematic review is to determine whether or not “Is safinamide 
effective as an add-on medication in treating Parkinson's disease motor symptoms?” !
Study design: Review of three randomized, controlled studies published in peer reviewed 
journals in English between 2012-2014. !
Data sources: The three randomized, double-blind clinical trials were found via PubMed and 
EBSCOhost Web. Articles were selected based on relevance, the date of publication, and whether 
or not they included patient outcomes. !
Outcomes measured: Among other measures, each trial measured improvement in motor 
symptoms using the Unified Parkinson’s Disease Rating Scale (UPDRS) Part III (motor) scores, 
a clinician-scored motor evaluation. !
Results: UPDRS III scores significantly improved in 100 mg/day safinamide experimental group 
compared to the placebo control group. !
Conclusions: All three of the randomized clinical trials included in this review indicated that 
safinamide 100 mg/day is an effective add-on medication to dopaminergic drugs in improving 
motor function and reducing motor fluctuations. !
Keywords: Safinamide, Parkinson’s disease, randomized or RCT  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Introduction 
 Parkinson’s disease (PD) is a progressive neurodegenerative disease resulting in diverse 
clinical features that include nonmotor symptoms, motor symptoms, and classic signs like 
tremor, akinesia, and rigidity.1 A single causative agent of PD is unknown. There is no direct 
evidence to support genetic or environmental factors as single causative agents but it is theorized 
that both are involved.2 There is evidence of six genes that have been implicated as causes of 
familial PD.2  
 The worldwide incidence of PD is about 315 per 100,000 for people 40 years and older, 
specifically 1,903 per 100,000 for the 80+ age group.3 With this data, the prevalence of PD is 
projected to be 7.5 million persons worldwide with a diagnosis.3 The prevalence in men is higher 
than women for all age groups.3 
 The population with PD acquired medical expenses of approximately $14 billion in 2010, 
57% of which is associated with nursing home services.4 Estimated medical costs alone 
attributed to PD were about $8 million in 2010, and another $6 million was estimated as indirect 
costs to the PD population like reduced household income and lost employment.4 The population 
with PD acquired approximately 1.9 million hospital inpatient days in 2010.4 Excess health-care 
use attributed to PD in 2010 includes 1.26 million physician office visits, 57,000 outpatient 
visits, 31,000 emergency visits, 24,000 home health days, and 26,000 hospice days.4 
 Pathologically PD is characterized by progressive death of dopaminergic neurons within 
the substantia nigra pars compacta.1 Levodopa remains one of the most effective drugs in treating 
PD because it’s converted into dopamine after crossing the blood brain barrier, however, one of 
the long term effects of the drug is dyskinesia. The motor complications, such as motor 
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fluctuations and dyskinesia, from levodopa are treated with other medications like monoamine 
oxidase type B inhibitors, amantadine, anticholinergics, β-blockers, or dopamine agonists.5 
 Monoamine oxidase-B (MAO-B) inhibitors are used to treat dyskinesia due to 
dopaminergic drug therapy. Safinamide is a reversible inhibitor of MAO-B and also exhibits 
inhibition of stimulated release of glutamate.6 The proposed connection between glutamate 
release and the development of dyskinesia supports the theory that safinamide, and its action 
against glutamate, will be successful in improving motor symptoms.6 This paper evaluates three 
randomized, double-blind, controlled trials comparing the efficacy of safinamide 100 mg/day at 
improving motor symptoms versus a placebo group. 
Objective 
 The objective of this systematic review is to determine whether or not safinamide is 
effective as an add-on medication in treating Parkinson's disease motor symptoms. 
Methods 
 Three double-blinded, randomized controlled trials were used in this review. The 
population includes PD patients with mid to late PD or a PD diagnosis of less than 5 years in 
duration. The intervention used was safinamide 100 mg/day as add-on therapy to levodopa or 
other dopaminergic drugs compared to a placebo group. The outcome being measured was the 
change in motor symptoms with the addition of safinamide 100 mg/day. This was measured by 
clinician scoring with the UPDRS Part III score, which focuses on motor symptoms. 
 The key words used while searching for relevant clinical trials were safinamide, 
Parkinson’s disease, randomized or RCT. All the articles were obtained through PubMed and 
EBSCOhost Web, and were selected based on the date of publication and whether or not they 
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included patient outcomes. All three articles were published in English in peer-reviewed journals, 
two in 2014 and one in 2012. The inclusion criteria for the studies included patients with a 
clinical diagnosis of PD, and randomized, controlled, double blind clinical trials. Exclusion 
criteria included patients who had previous safinamide treatment, evidence of dementia or 
psychiatric illness, and patients who had disabling dyskinesia or wide fluctuations. More detail is 
displayed below in Table 1 for each individual study exclusion and inclusion criteria. The 
statistics used and reported were numbers needed to harm (NNH), relative risk increase (RRI), 
absolute risk increase (ARI), and p-values. The demographics and characteristics of the included 
studies are shown below in Table 1. 
!
!
!
!
!
!
!
!
!
!
!
!
!
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Table 1: Demographics and characteristics of included studies 
Study Type Pts Age Inclusion criteria Exclusion criteria W/D Intervention
Borgohain, 
2014
RCT 669 30-80 
y/o
• motor fluctuations 
(> 1.5 hours’ off 
time/day) while 
receiving 
Levodopa and 
other dopaminergic 
treatments 
• clinical diagnosis 
of idiopathic PD >3 
years in duration 
• Hoehn and Yahr 
stage I to IV during 
off 
• able to accurately 
maintain a diary
• late-stage PD 
experiencing severe, 
disabling peak-dose or 
biphasic dyskinesia, or 
unpredictable or widely 
swinging symptom 
fluctuations 
• evidence of dementia, 
major psychiatric 
illnesses, and/or mental 
illnesses
29 safinamide 
100 mg/day 
or placebo 
as add-on 
therapy to 
Levodopa 
Borgohain, 
2014
RCT 669 mean 
age 60 
y/o
• mid-late stage PD 
with motor 
fluctuations 
• completed Study 
016 prior to Study 
018 
• treatment 
compliant, continue 
after Study 016 
• discontinued from 
Study 016 but had 
completed 
scheduled efficacy 
evaluations at 
weeks 12 and 24
• experienced clinically 
significant adverse 
effects during Study 016 
• showed clinically 
significant deterioration 
in motor symptoms
30 safinamide 
100 mg/day 
or placebo 
as add-on 
therapy to a 
single 
dopamine 
agonist 
Stocchi, 
2012
RCT 270 30-80 
y/o
• clinical diagnosis 
of idiopathic PD < 
5 years in duration 
• Hoehn and Yahr 
stage I to III 
• stable dose of 
dopamine agonist 
for at least 4 weeks 
before screening
• diagnosis of substance 
abuse 
• end-of-dose wearing off, 
on/off phenomena, 
disabling dyskinesia, or 
wide fluctuations 
• previous safinamide 
treatment 
• diagnosis of psychosis or 
depression 
• hypersensitivity to 
anticonvulsants or 
antiparkinsonian agents 
• severe postural 
hypotension 
• PD medications (except 
for a single DA) during 
the 4 wks before 
screening 
• concomitant use of 
MAO inhibitors
9 safinamide 
100 mg/day 
or placebo 
as add-on 
therapy to a 
single 
dopamine 
agonist 
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Outcomes measured 
 All three studies measured motor symptom outcomes with the UPDRS Part III scores, 
which is a measure of motor function done by a clinician.6,7,8 Motor fluctuations or dyskinesia 
experienced by patients in the experimental treatment groups were compared to placebo groups 
to determine whether or not they experienced statistically significant improvement in their 
UPDRS part III total score.6,7,8 
Results 
 This review of three RCTs compared patients with a PD diagnosis who were 
experiencing stable motor fluctuations while receiving levodopa treatment with changes after 
taking 100 mg/day of safinamide or a placebo. All three trials used safinamide 100 mg/day as an 
experimental group compared to another dose of safinamide and a placebo group. This 
systematic review focuses on the safinamide 100 mg/day experimental group in comparison to 
the placebo control group without mention of the other experimental treatment dose of 
safinamide. Dichotomous data was presented in all three RCTs to assess the safety and efficacy 
of the therapy.6,7,8 
 In the Borgohain study there were a total of 669 patients who enrolled, 224 patients 
randomized into the experimental safinamide 100 mg/day group and 222 patients randomized 
into the placebo group.7 Patient return visits throughout the study were held at 52 different sites 
in India, Romania, and Italy.7 Of the 224 patients in the safinamide 100 mg/day group, 195 
completed the study with 4 lost to follow up and 2 reports of noncompliance.7 Treatment 
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emergent adverse events (TEAEs) were experienced by 66% of patients in the safinamide 100 
mg/day group, but more than 90% of reported TEAEs were considered mild or moderate.7 Some 
of the common TEAEs reported by the safinamide 100 mg/day group were dyskinesia, cataract, 
back pain, headache, and hypertension.7 Five deaths were reported in the safinamide 100 mg/day 
group, 2 considered unrelated to the drug, 2 causes of death were unknown, and 1 death was a 
result of a posttraumatic subdural hematoma 49 days after discontinuation of the study.7 This 
cause of death was reported as a serious adverse event, but not considered a cause of death due to 
safinamide.7 In the experimental safinamide 100 mg/day group, 18.3% experienced dyskinesia.7 
The ARI was calculated to be 0.06.7 This means that patients taking safinamide 100 mg/day had 
a 6% absolute increase in experiencing dyskinesia. The NNH was calculated to be 17.7 This 
means that for every 17 patients being treated with safinamide 100 mg/day, one additional would 
experience dyskinesia compared to control. 
 In another Borgohain study that was a continuation of the preliminary Borgohain study, 
544 of the original 669 patients enrolled in a second continuation study that ended 78 weeks 
from the start of the first.6 The randomized assignment of patients to treatment groups was 
computer generated into an experimental safinamide 100 mg/day group and a placebo group.6 
Return visits at the 52 sites where the study was being conducted were held every 12 weeks.6 
Participants in the safinamide 100 mg/day experimental group were compliant to the study, with 
0 reports of noncompliance.6 Of the 180 patients in the safinamide 100 mg/day group at the start 
of the second study, 150 patients completed the study with 7 lost to follow up.6 TEAEs were 
similar across the treatment groups and the placebo control group.6 The highest incidence of 
newly emergent TEAEs, most common reported including worsening PD, dyskinesia, cataract, 
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constipation, back pain, etc., was seen in the placebo group with 85.1% of patients affected.6 No 
treatment related deaths occurred during the study.6 In the experimental safinamide 100 mg/day 
group, 27.8% experienced dyskinesia.6 The ARI was calculated to be 0.06 and NNH was 
calculated to be 17, the same as in the preliminary Borgohain study.6 This means that for every 
17 patients being treated with safinamide 100 mg/day, one additional would experience 
dyskinesia compared to control. 
 In the Stocchi study, 270 patients were randomized into study groups.8 The study was 
conducted at 26 centers in Italy, Spain, the United Kingdom, India, Argentina, Chile, and 
Colombia with return visits at weeks 2, 4, 8, 12, 18, and 24.8 Of the 90 patients in the 
experimental safinamide 100 mg/day group, 81 patients completed the study with 0 reports of 
noncompliance and 0 lost to follow up.8 TEAEs experienced across all study groups were mostly 
mild or moderate, and <10% experienced TEAEs in each group.8 Some of the most common 
included, nausea, abdominal pain, peripheral edema, dizziness, and tremor.8 Patients who 
reported severe TEAEs, retinal vein occlusion and iron-deficiency anemia, in the safinamide 100 
mg/day group totaled to 2.2% of the group, none of which caused death.8 In the experimental 
safinamide 100 mg/day group, 2.2% experienced dyskinesia.8 The ARI was calculated to be 
-0.045.8 This means that patients taking safinamide 100 mg/day had a -4.5% absolute increase in 
experiencing dyskinesia. The NNH was calculated to be -22.8 This means that for every 22 
patients being treated with safinamide 100 mg/day, one fewer would experience dyskinesia 
compared to control. 
!
!
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Table 2: Treatment effects 
!
Discussion 
 Safinamide, brand name Xadago, has been approved for treatment as an add-on to 
levodopa or in combination with other medications for mid to late stage PD patients experiencing 
motor fluctuations in the European Union, Iceland, Norway, and Lichtenstein.9 With a new drug 
application under review, the launch of safinamide is anticipated in the United States in the 
beginning months of 2016.9 A once daily preparation, safinamide 100 mg/day needs no 
laboratory monitoring, can be taken with or without food without affecting absorption, and 
doesn’t cause hallucinations or impulse control disorders like other PD medications.9,10 
 Safinamide is contraindicated for use in a patient with severe hepatic impairment as well 
as contraindicated for use in combination with other MAO inhibitors due to the risk of 
developing hypertensive crisis.9 It is not recommended to use safinamide with dextromethorphan 
and to be used with caution with sympathomimetic medicines.9 Use of tricyclic antidepressants, 
selective serotonin re-uptake inhibitors, and serotonin norepinephrine can cause severe adverse 
events when used with safinamide.9 If used with caution, antidepressant medications can be 
administered at the lowest effective doses with safinamide because of the selective and reversible 
nature of safinamide as a MAO-B inhibitor.9 This does not apply to fluvoxamine or fluoxetine, 
Study p-value CER EER RRI ARI NNH
Borgohain, 2014 0.0006 0.126 0.183 0.45 0.06 17
Borgohain, 2014 0.0002 0.217 0.278 0.28 0.06 17
Stocchi, 2012 0.0419 0.067 0.022 -0.67 -0.045 -22
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which should be avoided when the patient is already taking safinamide.9 Currently, there doesn’t 
seem to be any ongoing trials with safinamide.9 
 The RCTs on the effectiveness of safinamide in reducing motor fluctuation were limited 
by the age of the patient population. The Borgohain studies included a wide range of patients 
from 30-80 years old, but this didn’t include the subset of early onset PD which can affect 
someone as early as 21 years old.6,7,11 Early onset PD is characterized as 21-40 years old at the 
time of diagnosis, which comprises about 10% of the PD population.11 It would have been 
valuable to evaluate the effectiveness of the novel drug on a patient who is more likely to have 
familial PD with a diagnosis at a young age versus idiopathic PD. 
Conclusions 
 Is safinamide effective as an add-on medication in treating Parkinson's disease motor 
symptoms? The answer is yes. All three double-blinded RCTs provided statistically significant 
data that displayed improvement in UPDRS part III total scores after treatment with safinamide 
100 mg/day compared to placebo.6,7,8 The benefit of safinamide 100 mg/day as an add on 
medication to dopaminergic therapy in treating dyskinesia in patients with PD outweighs the 
mostly mild TEAEs recorded during the trials. For future study, more frequent return visits to 
study sites, similar to the Stocchi study schedule, can be recommended to improve patient 
compliance and dedication to the clinical trial. 
!
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